成人肾移植受者与等待名单患者双倍剂量肺炎球菌疫苗的免疫原性与安全性:一项非盲随机临床试验
这项3期非盲随机试验在74例肾移植受者和65例等待名单患者中比较双倍与常规剂量PCV13和PPV23序贯接种的免疫原性。等待名单患者中双倍剂量组在PPV23后5周达到保护性应答的比例为66.7%,高于常规剂量组的35.5%(p=0.015);肾移植受者未见剂量效应。疫苗安全、耐受良好,48周时仍具免疫原性。
要点
- 等待名单患者双倍剂量组保护性应答66.7%,高于常规剂量组35.5%(p=0.015)。
- 肾移植受者中未观察到双倍剂量与常规剂量的效应差异。
- PPV23后四组≥2倍升高的血清型数量均增加,疫苗安全且48周时仍具免疫原性。
核心结论
- 数据提示,按序贯策略使用双倍剂量肺炎球菌疫苗对等待名单患者可能值得推荐。
- 数据支持PPV23对PCV13在肾移植受者和等待名单患者中具有附加效应。
研究设计与样本
- 3期、随机、非盲临床试验,肾移植受者与等待名单患者平行分组,分别接种常规或双倍剂量的PCV13和PPV23,两剂间隔12周。
- 共纳入74例肾移植受者和65例等待名单患者,随访48周。
- 保护性应答定义为基于12种疫苗共享血清型特异性IgG抗体的平均几何平均浓度≥1 mg/L。
主要发现
- 等待名单患者中,双倍剂量组在PPV23后5周保护性应答比例为66.7%,常规剂量组为35.5%(p=0.015)。
- 肾移植受者中未观察到剂量效应。
- PPV23后,四组≥2倍升高的血清型数量均增加(等待名单患者两组p≤0.05;肾移植受者两组p≤0.01)。
- 疫苗安全、耐受良好,第48周时仍具免疫原性。
临床怎么用
- 作者认为,按序贯策略使用双倍剂量肺炎球菌疫苗对等待名单患者可能值得推荐。
- 作者认为数据支持PPV23对PCV13在肾移植受者和等待名单患者中的附加效应。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pneumococcal prime-boost vaccination is recommended for solid organ transplant recipients, but is not thoroughly tested in this population. Furthermore, a pneumococcal vaccine dose effect has never been investigated, though observed in healthy adults. To assess whether a double dose of 13-valent pneumococcal conjugate vaccine (PCV13) and of 23-valent pneumococcal polysaccharide vaccine (PPV23) increases the immunogenicity of prime-boost vaccination in kidney transplant recipients (KTRs) and patients on the kidney transplant waiting list (WLPs), a phase 3, randomized, non-blinded trial was conducted. METHODS: KTRs and WLPs were in parallel groups assigned either normal or double dosage of both vaccines 12 weeks apart. A 'protective response' was an average geometric mean concentration ≥ 1 mg/L based on 12 vaccine shared serotype-specific IgG antibodies. Furthermore, number of antibodies with ≥ 2-fold rises and individual serotype-specific antibody concentrations were evaluated. Follow-up was 48 weeks. RESULTS: Seventy-four KTRs and 65 WLPs were enrolled. In WLPs, double dosage resulted in a significantly higher proportion of participants with a 'protective response' (66.7%), 5 weeks after PPV23, compared to normal dosage (35.5%), p = 0.015. KTRs exhibited no dose effect. After PPV23, all four groups had increased their number of serotypes with ≥ 2-fold rises (p ≤ 0.05 for both WLPs groups; p ≤ 0.01 for both KTRs groups). Vaccines were safe, well tolerated and still immunogenic at week 48. CONCLUSIONS: Data suggests that double dosage of pneumococcal vaccines used according to the prime-boost strategy might be recommendable for WLPs. Furthermore, our data supports PPV23́s additive effect to PCV13 in KTRs and WLPs. (EudraCT: 2016-004123-23).
引用
- Larsen L, Bistrup C, Sørensen SS, et al. Immunogenicity and safety of double dosage of pneumococcal vaccines in adult kidney transplant recipients and waiting list patients: A non-blinded, randomized clinical trial. Vaccine. 2022. PMID: 35644672. doi:10.1016/j.vaccine.2022.05.040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。